Golden Green, Inc. Enlivex Therapeutics Ltd. Transaction History

Golden Green, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 18, 2022	SELL	$4.92 - $6.66 $98,237 - $132,980	-19,967 Closed	0 $0
Q4 2021 Jan 21, 2022	SELL	$5.81 - $9.73 $140,125 - $234,668	-24,118 Reduced 54.71%	19,967 $125,000
Q3 2021 Oct 08, 2021	SELL	$7.43 - $13.86 $14,377 - $26,819	-1,935 Reduced 4.2%	44,085 $436,000
Q2 2021 Jul 14, 2021	SELL	$8.61 - $12.1 $204,590 - $287,520	-23,762 Reduced 34.05%	46,020 $410,000
Q1 2021 Apr 13, 2021	BUY	$9.26 - $24.0 $219,702 - $569,424	23,726 Added 51.52%	69,782 $774,000
Q4 2020 Jan 25, 2021	BUY	$8.16 - $14.5 $375,816 - $667,812	46,056 New	46,056 $388,000

2.13M

16.1K

3.4K

Ticker ENLV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,403,200
Market Cap $23.4M
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...

Get notified when there are updates to the investment portfolio of Golden Green, Inc., based on Form 13F filings with the SEC.

Stay updated on Golden Green, Inc. with notifications on news.